Search clinical trials for: MORAb-003 (farletuzumab)

Total 2699 results

Morphotek

Completed

Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer

Epithelial Ovarian Cancer

United States
Morphotek

Withdrawn

Exploratory Study of Farletuzumab to Treat Resectable, Non-functioning Pituitary Adenomas

Resectable, Non-functioning Pituitary Adenoma

United States
Morphotek

Completed

Safety Study of Farletuzumab, Carboplatin and Pegylated Liposomal Doxorubicin (PLD) to Treat Platinum-sensitive Ovarian Cancer

Epithelial Ovarian Cancer

United States
Eisai Co., Ltd.

Completed

A Study of MORAb-003 in Patients With Solid Tumor

Neoplasms | Solid Tumor

Japan
Morphotek

Terminated

An Open Label Extension Study of the Efficacy of MORAb-003

Epithelial Ovarian Cancer

United States, Germany
Morphotek

Completed

Effectiveness of MORAb-003 in Women With Ovarian Cancer Who Have Relapsed After Platinum-Based Chemotherapy

Peritoneal Neoplasms | Ovarian Cancer | Fallopian Tube Cancer

United States, Germany
Morphotek
Eisai Europe Ltd. (United Kingdom)

Terminated

Efficacy and Safety of Farletuzumab (MORAb-003) in Combination With Carboplatin and Taxane in Participants With Platinum-sensitive Ovarian Cancer in First Relapse

Ovarian Cancer

United States, Hong Kong, Netherlands, Spain, Korea, Republic of, Belgium, Taiwan, Israel, Japan, France, United Kingdom, Singapore, Italy, Argentina, India, Germany, Hungary, Australia, Portugal, Russian Federation, Canada, Poland, Greec... and more
Eisai Inc.

Completed

A Study of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin) in Participants With Solid Tumors

Solid Tumors

Japan
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 in Participants With Previously Treated Metastatic Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma (AC)

Carcinoma, Non-Small-Cell Lung

United States, Australia, Belgium, Chile, France, Spain
University of Pennsylvania

Terminated

Penn Microbiome Therapy for Recurrent Clostridium Difficile Infection

Recurrent Clostridium Difficile Infection

United States
Revibe Technologies

Completed

Assessing a Wearable Digital Therapy for Youth With ADHD

ADHD

United States
Morphotek

Completed

A Single-Dose Pilot Study of Radiolabeled Amatuximab (MORAb-009) in Mesothelin Over Expressing Cancers

Pancreatic Cancer | Ovarian Cancer | Mesothelioma | Non-small Cell Lung Cancer

United States
Morphotek

Terminated

An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian Cancer (FAR-122)

Ovarian Cancer

Canada, United States, Netherlands, Spain, Belgium, Australia
Eisai Co., Ltd.

Completed

A Study of MORAb-009 in Patients With Solid Tumor

Cancer | Mesothelin-positive

Japan
Eisai Co., Ltd.

Completed

A Phase 1 Study of MORAb-004 in Patients With Solid Tumor (Study: MORAb-004-J081-103)

Solid Tumor

Japan
University of Pennsylvania

Terminated

Penn Microbiome Therapy (PMT) for Severe-Clostridium Difficile Infection (CDI)

Severe Clostridium Difficile Infection | Severe-Complicated/Fulminant Clostridium Difficile Infection

United States
EyeGene Inc.
Novotech (Australia) Pty Limited

Completed

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-HZ in Healthy Adult Volunteers

Prevention of Herpes Zoster (HZ)

Australia
Morphotek

Terminated

Morphotek Investigation in Colorectal Cancer: Research of MORAb-004 (MICRO)

Metastatic Colorectal Cancer | Colorectal Cancer

United States
Morphotek

Completed

A Study of MORAb-009 in Subjects With Pancreatic Cancer, Mesothelioma, or Certain Types of Ovarian or Lung Cancer

Pancreatic Cancer | Ovarian Cancer | Non-Small Cell Lung Cancer | Mesothelioma

United States
National Cancer Institute (NCI)

Terminated

Amatuximab for High Mesothelin Cancers

Carcinoma, Non-Small-Cell Lung | Ovarian Neoplasms | Mesothelioma | Carcinoma, Pancreatic Ductal

United States
University of Manitoba
Canadian Institutes of Health Research (CIHR); Canadian Cancer Society (CCS); The Canadian Collaborative for Childhood Cannabinoid Therapeutics

Not yet recruiting

CANnabinoids in Pediatric ONCology (CAN-PONC)

Cancer | Childhood Cancer
Morphotek

Completed

A Safety and Efficacy Study of Farletuzumab in Participants With Adenocarcinoma of the Lung

Adenocarcinoma of the Lung

Spain, United States, Australia, Canada, Germany, Italy, Poland, Russian Federation
Eisai Inc.
Bristol-Myers Squibb

Recruiting

A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

Solid Tumor

United States, Spain, United Kingdom, France
Morphotek
National Cancer Institute (NCI); Children's Oncology Group

Completed

MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma

Unspecified Childhood Solid Tumor, Protocol Specific | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma and other conditions

United States
Pfizer

Completed

A Study to Assess the Safety and Tolerability of Different Doses of PF-05402536 and PF-06413367 in Healthy Adult Smokers.

Smoking | Vaccines

Canada
Eisai Inc.

Completed

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

Platinum-Sensitive Ovarian Cancer in First Relapse

United States, Italy, United Kingdom, Germany, Spain, Belgium, Japan
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Study Evaluating EKB-569 in Advanced Colorectal Cancer

Colorectal Neoplasms | Rectal Neoplasms | Colonic Neoplasms
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Subjects With Asthma

Asthma
Dr. August Wolff GmbH & Co. KG Arzneimittel
Parexel

Completed

Safety, Tolerability, Pharmacokinetics and Efficacy of WOL071-007 in Atopic Dermatitis Patients

Dermatitis, Atopic

Germany
Bristol-Myers Squibb
Eisai Inc.

Recruiting

A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum-resistant High-grade Serous (HGS) Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Neoplasms, Ovarian

United States, Australia, Korea, Republic of, Japan, Belgium, Chile, Spain, Italy, Israel
PMG Pharm Co., Ltd

Completed

Study to Compare the Safety and Pharmacokinetics of PK101 With Coadministration of the Two Separate Drugs

Arthritis

Korea, Republic of
DermBiont, Inc.

Suspended

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Onychomycosis

Onychomycosis

United States
Eisai Inc.

Completed

Efficacy Study of Pharmacokinetic(PK)/Pharmacodynamic(PD) Relationship of Monotherapy MORAb-004 in Metastatic Melanoma

Metastatic Melanoma

United States, Australia, United Kingdom, Germany
EGEN, Inc.

Terminated

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

Ovarian Neoplasms

United States
EyeGene Inc.
Novotech (Australia) Pty Limited

Active, not recruiting

Study to Assess the Safety, Tolerability and Explore the Immunogenicity of EG-COVID and EG-COVARo in Healthy Adult Volunteers

COVID-19 Vaccine

Australia
Kukje Pharma

Completed

[KSR-001-P01]Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetic Characteristic of KSR-001

Dry Eye Syndromes

Korea, Republic of
Morphotek

Terminated

A Safety and MORAb-028 Dose Determination Study in Subjects With Metastatic Melanoma

Melanoma | Metastatic Melanoma | Advanced Melanoma | Malignant Metastatic Melanoma

United States
Morphotek

Completed

A Study of of MORAb-004 in Subjects With Solid Tumors

Solid Tumor

United States
DermBiont, Inc.

Active, not recruiting

A Trial to Evaluate the Safety and Efficacy of DBI-001 Gel, DBI-002 Gel, and Aqueous Gel in Subjects With Tinea Pedis

Tinea Pedis

United States
Hvivo
Prep Biopharm Limited

Completed

Study Examining PrEP-001 in Healthy Subjects

Influenza A H3N2

United Kingdom
Longbio Pharma

Active, not recruiting

A Study of Single and Multiple Doses of LP-003 in Healthy Adult Participants

Chronic Spontaneous Urticaria

China
Shenzhen NewDEL Biotech, Co., Ltd
Shenzhen Innovation Center for Small Molecule Drug Discovery Co., Ltd.

Not yet recruiting

A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults

Healthy
Emory University
National Cancer Institute (NCI); Prostate Cancer Foundation

Recruiting

Vidutolimod (CMP-001) in Combination With Nivolumab for the Treatment of Metastatic Castration Resistant Prostate Cancer

Stage IV Prostate Cancer AJCC v8 | Metastatic Prostate Adenocarcinoma

United States
University of North Carolina, Chapel Hill
Naturex SA

Completed

Botanical Supplement Muscle Function and Lean Body Mass

Healthy Volunteers

United States
Hyundai Pharmaceutical Co., LTD.

Completed

Change From Baseline to Chronic Kidney Disease Patient Before and After Administration Drug

Chronic Renal Failure
Medical University of Graz

Completed

Effects of Infliximab on Insulin Sensitivity and Beta Cell Function in Insulin Resistant Human Obesity

Obesity | Metabolic Syndrome | Insulin Resistance

Austria
Longbio Pharma

Recruiting

Efficacy and Safety of LP-003 in Moderate-to-severe Seasonal Allergic Rhinitis Adult

Seasonal Allergic Rhinitis

China
Huahui Health

Recruiting

A Study to Assess Efficacy and Safety of HH-003 Injection in Subjects With Chronic Hepatitis Delta Virus Infection

Chronic Hepatitis Delta Virus Infection

China
Stemcentrx

Terminated

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

Ovarian Cancer

United States
Wave Life Sciences Ltd.

Recruiting

Study of WVE-003 in Patients With Huntington's Disease

Huntington Disease

Canada, Spain, Australia, Denmark, Netherlands, Poland, United Kingdom, France, Germany, Italy

Search clinical trials for: MORAb-003 (farletuzumab)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Chile

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations